Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 101 articles: HTML format Text format

Single Articles

June 2018
1. VON MINCKWITZ G, Colleoni M, Kolberg HC, Morales S, et al
   Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
   Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30241.
   PubMed     Text format     Abstract available
   
   
   May 2018
2. MURTHY R, Borges VF, Conlin A, Chaves J, et al
   Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
   Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30256.
   PubMed     Text format     Abstract available
   
   
   
3. FOUKAKIS T
   Ribociclib in premenopausal women with advanced breast cancer.
   Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30367.
   PubMed     Text format    
   
   
   
4. TRIPATHY D, Im SA, Colleoni M, Franke F, et al
   Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
   Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30292.
   PubMed     Text format     Abstract available
   
   
   
5. BURKI TK
   Responses to carboplatin in BRCA1/2-mutated breast cancer.
   Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30407.
   PubMed     Text format    
   
   
   
6. GOURD E
   Low uptake of tamoxifen to prevent breast cancer.
   Lancet Oncol. 2018 May 3. pii: S1470-2045(18)30344.
   PubMed     Text format    
   
   
   April 2018
7. PERNAS S, Martin M, Kaufman PA, Gil-Martin M, et al
   Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
   Lancet Oncol. 2018 Apr 26. pii: S1470-2045(18)30147.
   PubMed     Text format     Abstract available
   
   
   
8. SCHAFER R, Strnad V, Polgar C, Uter W, et al
   Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
   Lancet Oncol. 2018 Apr 20. pii: S1470-2045(18)30195.
   PubMed     Text format     Abstract available
   
   
   
9. ECCLES DM, Copson ER
   Genetic testing for young women with breast cancer - Authors' reply.
   Lancet Oncol. 2018;19:e183.
   PubMed     Text format    
   
   
   
10. METCALFE K, Akbari MR, Narod SA
    Genetic testing for young women with breast cancer.
    Lancet Oncol. 2018;19:e182.
    PubMed     Text format    
    
    
    March 2018
11. MCGALE P, Dodwell D, Taylor C, Gray R, et al
    Neoadjuvant chemotherapy for early breast cancer - Author's reply.
    Lancet Oncol. 2018;19:e130.
    PubMed     Text format    
    
    
    
12. KRUG D, Loibl S
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e129.
    PubMed     Text format    
    
    
    
13. CHARALAMPOUDIS P, Karakatsanis A
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e128.
    PubMed     Text format    
    
    
    February 2018
14. CURIGLIANO G
    Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30129.
    PubMed     Text format    
    
    
    
15. LOIBL S, O'Shaughnessy J, Untch M, Sikov WM, et al
    Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111.
    PubMed     Text format     Abstract available
    
    
    
16. DE PLACIDO S, Gallo C, De Laurentiis M, Bisagni G, et al
    Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 23. pii: S1470-2045(18)30116.
    PubMed     Text format     Abstract available
    
    
    
17. WILDIERS H, Tryfonidis K, Dal Lago L, Vuylsteke P, et al
    Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Lancet Oncol. 2018 Feb 9. pii: S1470-2045(18)30083.
    PubMed     Text format     Abstract available
    
    
    
18. BIANUCCI R, Perciaccante A, Charlier P, Appenzeller O, et al
    Earliest evidence of malignant breast cancer in Renaissance paintings.
    Lancet Oncol. 2018;19:166-167.
    PubMed     Text format    
    
    
    January 2018
19. FASCHING PA
    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(18)30008.
    PubMed     Text format    
    
    
    
20. COPSON ER, Maishman TC, Tapper WJ, Cutress RI, et al
    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(17)30891.
    PubMed     Text format     Abstract available
    
    
    
21. GIANNI L, Bisagni G, Colleoni M, Del Mastro L, et al
    Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30001.
    PubMed     Text format     Abstract available
    
    
    
22. PIVOT X, Cox DG
    A new era for treatment development in HER2-positive breast cancer.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30002.
    PubMed     Text format    
    
    
    
23. MALAGA G, Cuba-Fuentes S, Romero-Albino Z
    Implementation of a community-based breast cancer management programme.
    Lancet Oncol. 2018;19:e3.
    PubMed     Text format    
    
    
    December 2017
24. BURKI TK
    Improved progression-free survival in metastatic breast cancer.
    Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30952.
    PubMed     Text format    
    
    
    
25. NELSON R
    San Antonio Breast Cancer Symposium 2017.
    Lancet Oncol. 2017 Dec 14. pii: S1470-2045(17)30930.
    PubMed     Text format    
    
    
    
26. DERKS MGM, van de Velde CJH
    Neoadjuvant chemotherapy in breast cancer: more than just downsizing.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30914.
    PubMed     Text format    
    
    
    
27. 
    Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30777.
    PubMed     Text format     Abstract available
    
    
    
28. SALGADO R, Loi S
    Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30905.
    PubMed     Text format    
    
    
    
29. DENKERT C, von Minckwitz G, Darb-Esfahani S, Lederer B, et al
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30904.
    PubMed     Text format     Abstract available
    
    
    
30. DI LEO A, Johnston S, Lee KS, Ciruelos E, et al
    Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Dec 6. pii: S1470-2045(17)30688.
    PubMed     Text format     Abstract available
    
    
    
31. HO AY, Hu ZI, Mehrara BJ, Wilkins EG, et al
    Radiotherapy in the setting of breast reconstruction: types, techniques, and timing.
    Lancet Oncol. 2017;18:e742-e753.
    PubMed     Text format     Abstract available
    
    
    November 2017
32. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
    Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
    PubMed     Text format     Abstract available
    
    
    
33. COLLEONI M, Luo W, Karlsson P, Chirgwin J, et al
    Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 17. pii: S1470-2045(17)30715.
    PubMed     Text format     Abstract available
    
    
    
34. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
    PubMed     Text format     Abstract available
    
    
    
35. CHAVEZ-MACGREGOR M, Mittendorf EA
    Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
    PubMed     Text format    
    
    
    
36. GOURD E
    Thermography should not be used in breast cancer screening.
    Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30833.
    PubMed     Text format    
    
    
    October 2017
37. COSTA L, Ferreira AR
    Adjuvant zoledronic acid to treat breast cancer: not for all.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30695.
    PubMed     Text format    
    
    
    
38. COLEMAN R, Hall A, Albanell J, Hanby A, et al
    Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30603.
    PubMed     Text format     Abstract available
    
    
    
39. GOURD E
    Insulin analog linked to breast cancer risk.
    Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30772.
    PubMed     Text format    
    
    
    
40. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
    Resource-stratified implementation of a community-based breast cancer management programme in Peru.
    Lancet Oncol. 2017;18:e607-e617.
    PubMed     Text format     Abstract available
    
    
    
41. PINEROS M, Ramos W, Antoni S, Abriata G, et al
    Cancer patterns, trends, and transitions in Peru: a regional perspective.
    Lancet Oncol. 2017;18:e573-e586.
    PubMed     Text format     Abstract available
    
    
    September 2017
42. GOURD E
    Pyrotinib shows activity in metastatic breast cancer.
    Lancet Oncol. 2017 Sep 21. pii: S1470-2045(17)30755.
    PubMed     Text format    
    
    
    
43. EICHBAUM MHR, Kissel N, Neunhoeffer T, Dollas L, et al
    Hypoglossal paresis caused by a solitary breast cancer metasasis at the basal skull.
    Lancet Oncol. 2017;18:e552.
    PubMed     Text format    
    
    
    August 2017
44. DELALOGE S, DeForceville L
    Targeting PI3K/AKT pathway in triple-negative breast cancer.
    Lancet Oncol. 2017 Aug 8. pii: S1470-2045(17)30514.
    PubMed     Text format    
    
    
    
45. KIM SB, Dent R, Im SA, Espie M, et al
    Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2017 Aug 8. pii: S1470-2045(17)30450.
    PubMed     Text format     Abstract available
    
    
    
46. KERR J, Anderson C, Lippman SM
    Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
    Lancet Oncol. 2017;18:e457-e471.
    PubMed     Text format     Abstract available
    
    
    
47. LEVIS BE, Binkley PF, Shapiro CL
    Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Lancet Oncol. 2017;18:e445-e456.
    PubMed     Text format     Abstract available
    
    
    July 2017
48. DERKS MGM, Blok EJ, Seynaeve C, Nortier JWR, et al
    Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Jul 18. pii: S1470-2045(17)30419.
    PubMed     Text format     Abstract available
    
    
    
49. MATHEW A, Brufsky A
    TACT2: improving treatment tolerability in early breast cancer.
    Lancet Oncol. 2017;18:843-845.
    PubMed     Text format    
    
    
    June 2017
50. DAS M
    Adjuvant pertuzumab improves early breast cancer outcomes.
    Lancet Oncol. 2017 Jun 15. pii: S1470-2045(17)30481.
    PubMed     Text format    
    
    
    
51. DAS M
    Olaparib provides benefit in metastatic breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30453.
    PubMed     Text format    
    
    
    
52. BURKI TK
    Adjuvant capecitabine for HER2-negative breast cancer.
    Lancet Oncol. 2017 Jun 8. pii: S1470-2045(17)30451.
    PubMed     Text format    
    
    
    
53. CAMERON D, Morden JP, Canney P, Velikova G, et al
    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, co
    Lancet Oncol. 2017 Jun 6. pii: S1470-2045(17)30404.
    PubMed     Text format     Abstract available
    
    
    
54. STEBBING J, Baranau Y, Baryash V, Manikhas A, et al
    CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
    Lancet Oncol. 2017 Jun 2. pii: S1470-2045(17)30434.
    PubMed     Text format     Abstract available
    
    
    May 2017
55. CHOPRA N, Turner NC
    Targeting PIK3CA-mutant advanced breast cancer in the clinical setting.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30430.
    PubMed     Text format    
    
    
    
56. BASELGA J, Im SA, Iwata H, Cortes J, et al
    Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 May 30. pii: S1470-2045(17)30376.
    PubMed     Text format     Abstract available
    
    
    
57. KROP IE, Kim SB, Martin AG, LoRusso PM, et al
    Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30313.
    PubMed     Text format     Abstract available
    
    
    
58. MONTEMURRO F
    Trastuzumab emtansine in HER2-positive metastatic breast cancer.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30303.
    PubMed     Text format    
    
    
    
59. DIERAS V, Miles D, Verma S, Pegram M, et al
    Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2017 May 16. pii: S1470-2045(17)30312.
    PubMed     Text format     Abstract available
    
    
    
60. ALLGOOD PC, Maroni R, Hudson S, Offman J, et al
    Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
    Lancet Oncol. 2017 May 15. pii: S1470-2045(17)30340.
    PubMed     Text format     Abstract available
    
    
    
61. GOURD E
    Switch to exemestane effective in early breast cancer.
    Lancet Oncol. 2017 May 11. pii: S1470-2045(17)30341.
    PubMed     Text format    
    
    
    
62. EARL HM, Hiller L, Howard HC, Dunn JA, et al
    Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 May 4. pii: S1470-2045(17)30319.
    PubMed     Text format     Abstract available
    
    
    April 2017
63. FOUAD TM, Barrera AM, Reuben JM, Lucci A, et al
    Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.
    Lancet Oncol. 2017;18:e228-e232.
    PubMed     Text format     Abstract available
    
    
    March 2017
64. BURKI TK
    Sacituzumab govitecan activity in advanced breast cancer.
    Lancet Oncol. 2017 Mar 23. pii: S1470-2045(17)30232.
    PubMed     Text format    
    
    
    
65. RUGO HS, Seneviratne L, Beck JT, Glaspy JA, et al
    Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Lancet Oncol. 2017 Mar 14. pii: S1470-2045(17)30109.
    PubMed     Text format     Abstract available
    
    
    February 2017
66. MAYOR S
    Service review: improving breast cancer care in Tanzania.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30160.
    PubMed     Text format    
    
    
    
67. MATHEW A, Brufsky A
    Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30150.
    PubMed     Text format    
    
    
    
68. BROWER V
    Scalp cooling and hair loss during breast cancer chemotherapy.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30158.
    PubMed     Text format    
    
    
    
69. LLOMBART-CUSSAC A, Cortes J, Pare L, Galvan P, et al
    HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Lancet Oncol. 2017 Feb 23. pii: S1470-2045(17)30021.
    PubMed     Text format     Abstract available
    
    
    
70. ZHANG P, Sun T, Zhang Q, Yuan Z, et al
    Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Lancet Oncol. 2017 Feb 10. pii: S1470-2045(17)30088.
    PubMed     Text format     Abstract available
    
    
    
71. BROWER V
    Letrozole not superior to anastrozole for early breast cancer.
    Lancet Oncol. 2017 Feb 2. pii: S1470-2045(17)30081.
    PubMed     Text format    
    
    
    
72. POLGAR C, Ott OJ, Hildebrandt G, Kauer-Dorner D, et al
    Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year r
    Lancet Oncol. 2017;18:259-268.
    PubMed     Text format     Abstract available
    
    
    
73. DIKMANS RE, Negenborn VL, Bouman MB, Winters HA, et al
    Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.
    Lancet Oncol. 2017;18:251-258.
    PubMed     Text format     Abstract available
    
    
    January 2017
74. LUEN SJ, Salgado R, Fox S, Savas P, et al
    Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Lancet Oncol. 2017;18:52-62.
    PubMed     Text format     Abstract available
    
    
    December 2016
75. TANDAY S
    Duloxetine lessens joint pain in early-stage breast cancer.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30656.
    PubMed     Text format    
    
    
    
76. GOURD K
    San Antonio Breast Cancer Symposium 2016.
    Lancet Oncol. 2016 Dec 15. pii: S1470-2045(16)30658.
    PubMed     Text format    
    
    
    
77. BURKI TK
    Incidence of breast cancer in women with type 2 diabetes.
    Lancet Oncol. 2016;17:e523.
    PubMed     Text format    
    
    
    November 2016
78. BURKI TK
    Palbociclib improves survival in advanced breast cancer.
    Lancet Oncol. 2016 Nov 24. pii: S1470-2045(16)30619.
    PubMed     Text format    
    
    
    
79. VENKATESAN P
    Trastuzumab emtansine for HER2-positive breast cancer.
    Lancet Oncol. 2016 Nov 17. pii: S1470-2045(16)30589.
    PubMed     Text format    
    
    
    October 2016
80. BURKI TK
    Ribociclib in HR-positive, HER2-negative breast cancer.
    Lancet Oncol. 2016 Oct 13. pii: S1470-2045(16)30502.
    PubMed     Text format    
    
    
    
81. JATOI I, Benson JR, Toi M
    De-escalation of axillary surgery in early breast cancer.
    Lancet Oncol. 2016;17:e430-e441.
    PubMed     Text format     Abstract available
    
    
    September 2016
82. ASDOURIAN MS, Skolny MN, Brunelle C, Seward CE, et al
    Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis.
    Lancet Oncol. 2016;17:e392-405.
    PubMed     Text format     Abstract available
    
    
    August 2016
83. BALAKRISHNAN VS
    Physical exercise might affect breast cancer outcomes.
    Lancet Oncol. 2016 Aug 11. pii: S1470-2045(16)30389.
    PubMed     Text format    
    
    
    
84. BRUFSKY A
    Is there room for bevacizumab in metastatic breast cancer?
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30295.
    PubMed     Text format    
    
    
    
85. ZIELINSKI C, Lang I, Inbar M, Kahan Z, et al
    Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Lancet Oncol. 2016 Aug 5. pii: S1470-2045(16)30154.
    PubMed     Text format     Abstract available
    
    
    July 2016
86. TANDAY S
    IVF treatment not linked to breast cancer.
    Lancet Oncol. 2016 Jul 21. pii: S1470-2045(16)30371.
    PubMed     Text format    
    
    
    
87. BAKER H
    Adaptive treatments show promise in breast cancer.
    Lancet Oncol. 2016 Jul 14. pii: S1470-2045(16)30315.
    PubMed     Text format    
    
    
    
88. GHISLAIN I, Zikos E, Coens C, Quinten C, et al
    Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.
    Lancet Oncol. 2016;17:e294-304.
    PubMed     Text format     Abstract available
    
    
    June 2016
89. BERNARDI D, Macaskill P, Pellegrini M, Valentini M, et al
    Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.
    Lancet Oncol. 2016 Jun 23. pii: S1470-2045(16)30101.
    PubMed     Text format     Abstract available
    
    
    
90. VAN MAAREN MC, de Munck L, de Bock GH, Jobsen JJ, et al
    10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.
    Lancet Oncol. 2016 Jun 22. pii: S1470-2045(16)30067.
    PubMed     Text format     Abstract available
    
    
    
91. BERTUCCI F, Viens P, Birnbaum D
    SPAG5: the ultimate marker of proliferation in early breast cancer?
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)30092.
    PubMed     Text format    
    
    
    
92. ABDEL-FATAH TM, Agarwal D, Liu DX, Russell R, et al
    SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Lancet Oncol. 2016 Jun 13. pii: S1470-2045(16)00174.
    PubMed     Text format     Abstract available
    
    
    May 2016
93. GIANNI L, Pienkowski T, Im YH, Tseng LM, et al
    5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Lancet Oncol. 2016 May 11. pii: S1470-2045(16)00163.
    PubMed     Text format     Abstract available
    
    
    
94. BACHELOT T, Campone M, Tredan O
    PI3K targeting in breast cancer: the end of the beginning?
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00148.
    PubMed     Text format    
    
    
    
95. KROP IE, Mayer IA, Ganju V, Dickler M, et al
    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2016 May 4. pii: S1470-2045(16)00106.
    PubMed     Text format     Abstract available
    
    
    
96. CHAN A, Buyse M, Yao B
    Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply.
    Lancet Oncol. 2016;17:e176-7.
    PubMed     Text format    
    
    
    
97. HASEGAWA T, Uno H, Wei LJ
    Neratinib after trastuzumab in patients with HER2-positive breast cancer.
    Lancet Oncol. 2016;17:e176.
    PubMed     Text format    
    
    
    February 2016
98. BURKI TK
    Happygram.
    Lancet Oncol. 2016;17:152.
    PubMed     Text format    
    
    
    
99. BAKER H
    Familial risk in patients with carcinoma of unknown primary.
    Lancet Oncol. 2016;17:e48.
    PubMed     Text format    
    
    
    January 2016
100. EVANS A
     Detection of DCIS and reduced invasive interval cancers.
     Lancet Oncol. 2016;17:14-5.
     PubMed     Text format    
     
     
     
101. BALAKRISHNAN VS
     Patient risk factors versus physician guidelines for anti-emetics.
     Lancet Oncol. 2016;17:e7.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: